1. Home
  2. ACET vs SNCR Comparison

ACET vs SNCR Comparison

Compare ACET & SNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACET
  • SNCR
  • Stock Information
  • Founded
  • ACET 1947
  • SNCR 2000
  • Country
  • ACET United States
  • SNCR United States
  • Employees
  • ACET N/A
  • SNCR N/A
  • Industry
  • ACET Biotechnology: Pharmaceutical Preparations
  • SNCR EDP Services
  • Sector
  • ACET Health Care
  • SNCR Technology
  • Exchange
  • ACET Nasdaq
  • SNCR Nasdaq
  • Market Cap
  • ACET 60.5M
  • SNCR 70.9M
  • IPO Year
  • ACET N/A
  • SNCR 2006
  • Fundamental
  • Price
  • ACET $0.72
  • SNCR $6.02
  • Analyst Decision
  • ACET Strong Buy
  • SNCR Strong Buy
  • Analyst Count
  • ACET 7
  • SNCR 1
  • Target Price
  • ACET $5.60
  • SNCR $13.00
  • AVG Volume (30 Days)
  • ACET 679.5K
  • SNCR 67.1K
  • Earning Date
  • ACET 08-07-2025
  • SNCR 08-11-2025
  • Dividend Yield
  • ACET N/A
  • SNCR N/A
  • EPS Growth
  • ACET N/A
  • SNCR N/A
  • EPS
  • ACET N/A
  • SNCR N/A
  • Revenue
  • ACET N/A
  • SNCR $171,870,000.00
  • Revenue This Year
  • ACET N/A
  • SNCR $1.51
  • Revenue Next Year
  • ACET N/A
  • SNCR $5.43
  • P/E Ratio
  • ACET N/A
  • SNCR N/A
  • Revenue Growth
  • ACET N/A
  • SNCR 2.54
  • 52 Week Low
  • ACET $0.45
  • SNCR $5.88
  • 52 Week High
  • ACET $1.63
  • SNCR $15.46
  • Technical
  • Relative Strength Index (RSI)
  • ACET 52.09
  • SNCR 37.22
  • Support Level
  • ACET $0.64
  • SNCR $6.11
  • Resistance Level
  • ACET $0.78
  • SNCR $6.28
  • Average True Range (ATR)
  • ACET 0.06
  • SNCR 0.37
  • MACD
  • ACET 0.01
  • SNCR -0.05
  • Stochastic Oscillator
  • ACET 68.33
  • SNCR 9.09

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

About SNCR Synchronoss Technologies Inc.

Synchronoss Technologies Inc is a provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.

Share on Social Networks: